1. Division of Bone Biology, Garvan Institute of Medical Research, Sydney, NSW, Australia;
2. School of Biotechnology and Biomolecular Sciences, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia;
3. Department of Immunology, Weizmann Institute of Science, Rehovot, Israel;
4. Department of Internal Medicine “T”, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel;
5. Cancer Division, Garvan Institute of Medical Research, Sydney, NSW, Australia;
6. St Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia;
7. Department of Hematology and Immunology, Vrije Universiteit Brussel, Brussels, Belgium;
8. Department of Biochemistry and Genetics, La Trobe University, Melbourne, VIC, Australia;
9. Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia;
10. Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia;
11. Labor für Myelomforschung, Medizinische Klinik V, Universitätsklinikum Heidelberg, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany;
12. Department of Anatomy and Clinical Anatomy, University of Zagreb School of Medicine, Zagreb, Croatia;
13. Immunology Division, Garvan Institute of Medical Research, Sydney, NSW, Australia;
14. J. Craig Venter Institute, La Jolla, CA;
15. School of Biomedical Engineering, University of Technology, Sydney, NSW, Australia;
16. Department of Cell Systems and Anatomy, Long School of Medicine, and
17. Mays Cancer Center, University of Texas Health Science Center, San Antonio, TX; and
18. Exelixis Inc, Alameda, CA